Abstract 3504
Abstract 3504 Oral maintenance capecitabine versus active monitoring for patients with metastatic colorectal cancer (mCRC) who are stable or responding after 16 weeks of first-line treatment: Results from the randomized…
Abstract LBA4001
Abstract LBA4001 Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): First results of the CheckMate…
Abstract 4007
Abstract 4007 Hepatic arterial infusion chemotherapy of oxaliplatin plus fluorouracil versus sorafenib in advanced hepatocellular carcinoma: A biomolecular exploratory, randomized, phase 3 trial (The FOHAIC-1 study). Ning Lyu, Ming ZhaoBackground:…
Abstract 4006
Abstract 4006 Liposomal irinotecan (nal-IRI) in combination with fluorouracil (5-FU) and leucovorin (LV) for patients with metastatic biliary tract cancer (BTC) after progression on gemcitabine plus cisplatin (GemCis): Multicenter comparative…
Abstract 1003
Abstract 1003 Trastuzumab plus endocrine therapy or chemotherapy as first-line treatment for metastatic breast cancer with hormone receptor-positive and HER2-positive: The sysucc-002 randomized clinical trial. Zhongyu Yuan, Jia-Jia Huang, Xin…
Abstract 5000
Abstract 5000 A phase 3 trial with a 2x2 factorial design of abiraterone acetate plus prednisone and/or local radiotherapy in men with de novo metastatic castration-sensitive prostate cancer (mCSPC): First…
Abstract LBA5
Abstract LBA4 Pembrolizumab versus placebo as post nephrectomy adjuvant therapy for patients with renal cell carcinoma: Randomized, double-blind, phase 3 KEYNOTE-564 study. Toni K. Choueiri, Piotr Tomczak, Se Hoon Park,…
Abstract LBA4
Abstract LBA4 Phase 3 study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION). Michael J. Morris, Johann S. De Bono, Kim N. Chi, Karim Fizazi, Ken Herrmann, Kambiz…
Abstract 3505
Abstract 3505 Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): Final results from a phase 2, multicenter, open-label study (DESTINY-CRC01). Takayuki Yoshino, Maria Di Bartolomeo,…
Abstract 4500
Abstract 4500 Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of KEYNOTE-426. Brian I. Rini, Elizabeth…